Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(1):7–11. doi: 10.1111/j.1349-7006.2004.tb03163.x

Isolation of p53‐target genes and their functional analysis

Yusuke Nakamura 1,✉
PMCID: PMC11158342  PMID: 14720320

Abstract

Mutations of the p53 gene are the most common genetic alterations found in human cancers, and are known to play crucial roles in tumor development and progression. The p53 gene encodes a protein functioning as a transcription factor, and the biological functions of p53 are manifested through the activities of its downstream genes. Identification of these downstream genes involved in the p53‐signaling pathway should provide more detailed insight into the molecular mechanisms that mediate tumor‐suppressor activities, as well as various responses to cellular stress. We have been attempting to isolate p53‐target genes by means of various approaches, including differential display, cDNA microarray analysis, and direct cloning of the p53‐binding sequences from human genomic DNA. Here I review our recent work on isolation of p53‐target genes and their functional analysis. The physiological functions of p53‐target genes include apoptosis (GML, p53AIP1, and STAG1), DNA repair (p53R2), inhibition of angiogenesis (BAI1), re‐entry into the cell cycle (p53RFP), oxidative stress (CSR), and determination of cell fate (p53RDL1). (Cancer Sci 2004; 95: 7–11)

References

  • 1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science 1991; 253: 49–53. [DOI] [PubMed] [Google Scholar]
  • 2. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53‐regulated gene expression. Science 1991; 252: 1708–11. [DOI] [PubMed] [Google Scholar]
  • 3. Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45: 1437–43. [PubMed] [Google Scholar]
  • 4. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299–303. [DOI] [PubMed] [Google Scholar]
  • 5. Tokino T, Thiagalingam S, El‐Deiry WS, Waldman T, Kinzler KW, Vogelstein B. p53 tagged sites from human genomic DNA. Hum Mol Genet 1994; 3: 1537–42. [DOI] [PubMed] [Google Scholar]
  • 6. Furuhata T, Urano T, Tokino T, Nakamura Y. Isolation of a novel GPI‐anchored gene specifically regulated by p53, and correlation between its expression and anti‐cancer drug sensitivity. Oncogene 1996; 13: 1965–70. [PubMed] [Google Scholar]
  • 7. Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K, Yoshida S, Ono M, Kuwano M, Nakamura Y, Tokino T. A novel brain‐specific p53‐target gene, BAI1, containing thrombospondin type1 repeats inhibits experimental angiogenesis. Oncogene 1997; 15: 2145–50. [DOI] [PubMed] [Google Scholar]
  • 8. Takei Y, Ishikawa S, Tokino T, Muto T, Nakamura Y. Isolation of a novel p53‐target gene from a colon‐cancer cell line carrying a highly‐regulated wild‐type p53 expression system. Genes Chromosom Cancer 1998; 23: 1–9. [PubMed] [Google Scholar]
  • 9. Okamura S, Ng CC, Koyama K, Takei Y, Monden M, Nakamura Y. Identification of seven genes regulated by wild‐type p53 in a colon‐cancer cell line carrying a well‐controlled wild‐type p53 expression system. Oncol Res 1999; 11: 281–5. [PubMed] [Google Scholar]
  • 10. Tanaka H, Arakawa H, Shiraishi K, Yamaguchi T, Takei Y, Nakamura Y. A ribonucleotide reductase gene involved in a p53 dependent DNA damage checkpoint. Nature 2000; 404: 42–9. [DOI] [PubMed] [Google Scholar]
  • 11. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, Arakawa H. p53R2‐dependent pathway for DNA synthesis in a p53‐regulated cell‐cycle checkpoint. Cancer Res 2001; 61: 8256–62. [PubMed] [Google Scholar]
  • 12. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b‐null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 2003; 34: 440–5. [DOI] [PubMed] [Google Scholar]
  • 13. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. Isolation of a novel gene encoding a mitochondrial protein, p53AIP1, a potential mediator of p53‐dependent apoptosis, and its regulation by Ser46‐phosphorylated p53. Cell 2000; 102: 849–62. [DOI] [PubMed] [Google Scholar]
  • 14. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002; 62: 2883–9. [PubMed] [Google Scholar]
  • 15. Kimura Y, Furuhata T, Urano T, Hirata K, Nakamura Y, Tokino T. Genomic structure and chromosomal localization of GML (GPI‐anchored molecule‐like protein), a gene induced by p53. Genomics 1997; 41: 477–80. [DOI] [PubMed] [Google Scholar]
  • 16. Ueda K, Miyoshi Y, Tokino T, Watatani M, Nakamura Y. Induction of apoptosis in T98G glioblastoma cells by transfection of GML, a p53‐target gene. Oncol Res 1999; 11: 125–32. [PubMed] [Google Scholar]
  • 17. Iiizumi M, Arakawa H, Mori T, Ando A, Nakamura Y. Isolation of a novel human p53‐target gene encoding a mitochondrial protein, p53ABC1L, that is highly homologous to yeast activity of bc1 complex. Cancer Res 2002; 62: 1246–50. [PubMed] [Google Scholar]
  • 18. Anazawa Y, Arakawa H, Nakagawa H, Nakamura Y. Identification of STAG1 as a key mediator of a p53‐dependent apoptotic pathway. Oncogene in press. [DOI] [PubMed] [Google Scholar]
  • 19. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin‐1. Science 1994; 265: 1582–4. [DOI] [PubMed] [Google Scholar]
  • 20. Oda K, Shiratsuchi T, Nishimori H, Inazawa J, Yoshikawa H, Taketani Y, Nakamura Y, Tokino T. Identification of BAIAP2 (BAI‐associated protein 2), a novel human homologue of hamster IRSp53, whose SH3 domain interacts with the cytoplasmic domain of BAI1. Cytogenet Cell Genet 1999; 84: 75–82. [DOI] [PubMed] [Google Scholar]
  • 21. Han HJ, Tokino T, Nakamura Y. CSR, a scavenger receptor‐like gene with a protective role from cell death caused by UV irradiation and oxidative stress. Hum Mol Genet 1998; 7: 1039–46. [DOI] [PubMed] [Google Scholar]
  • 22. Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, Ogawa M, Nakamura Y, Arakawa H. Identification of fractalkine, a CX3C‐type chemokine, as a direct target of p53. Cancer Res 2000; 60: 3722–6. [PubMed] [Google Scholar]
  • 23. Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF‐5) as a direct target for p53. Oncogene 2002; 21: 2914–8. [DOI] [PubMed] [Google Scholar]
  • 24. Mori T, Anazawa Y, Matsui K, Fukuda S, Nakamura Y, Arakawa H. Cyclin K as a direct transcriptional target of the p53 tumor suppressor. Neoplasia 2002; 4: 268–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Kimura T, Gotoh M, Nakamura Y, Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Science 2003; 94: 431–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Ng CC, Arakawa H, Fukuda S, Kondoh H, Nakamura Y. p53RFP, a p53‐inducible RING‐finger protein, regulates the stability of p21WAF1 . Oncogene 2003; 22: 4449–58. [DOI] [PubMed] [Google Scholar]
  • 27. Tanikawa C, Matsuda K, Fukuda S, Nakamura Y, Arakawa H. p53RDL1UNC5B as a positive and negative regulator of p53‐dependent apoptosis. Nature Cell Biol 2003; 5: 216–23. [DOI] [PubMed] [Google Scholar]
  • 28. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M, Nakamura Y. p53DINP1, a p53‐inducible gene, regulates p53‐dependent apoptosis. Mol Cell 2001; 8: 85–94. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES